Niino Masaaki, Miyazaki Yusei
Department of Clinical Research, National Hospital Organization Hokkaido Medical Center.
Brain Nerve. 2021 May;73(5):442-449. doi: 10.11477/mf.1416201784.
Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the central nervous system. There are neither diagnostic tests nor markers for MS. Other causes must be excluded thoroughly before an MS diagnosis is considered definitive. The relapsing-remitting type is a major clinical course in MS. Most disease-modifying drugs (DMDs) target this clinical type. Many clinical studies have demonstrated that early intervention with DMDs may prevent disease progression and transition from relapsing-remitting MS to the secondary progressive type. There are windows of opportunity for DMDs. An adequate DMD should be used for the appropriate patient at the optimal time.
多发性硬化症(MS)是一种中枢神经系统的免疫介导性炎症性脱髓鞘疾病。目前尚无MS的诊断测试或标志物。在MS诊断被认为确定之前,必须彻底排除其他病因。复发缓解型是MS的主要临床病程。大多数疾病修正药物(DMDs)针对这种临床类型。许多临床研究表明,早期使用DMDs进行干预可能会预防疾病进展以及从复发缓解型MS转变为继发进展型。DMDs存在治疗时机。应在最佳时间为合适的患者使用适当的DMD。